Magazine article from our research archive:
|
|
Experimental drug slows HER2-positive cancer.(News)
- Article from:
-
OB GYN News
- Article date:
-
July 15, 2006
- Author:
-
|
Copyright informationCOPYRIGHT 2006 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ATLANTA -- The investigational drug lapatinib slows disease progression in women with advanced or metastatic HER2-positive breast cancer that has become resistant to targeted therapy with trastuzumab.
Lapatinib (Tykerb) nearly doubled the time to recurrence for heavily pretreated patients when combined with capecitabine in an international, multicenter, phase III trial presented at the annual meeting of the American Society of Clinical Oncology.
Dr. Charles E. Geyer Jr. reported the median time to progression was 37 weeks for 160 women treated with the two-drug combination, but only 20 weeks for 161 women given capecitabine alone.
"Cutting the hazard in half is ...
Related newspaper, magazine, and journal articles:
|
Oral Anticancer Drug Provides New Promise for Advanced Breast Cancer...
PR Newswire;
February 8, 2001 ;
427 words
......care. The Role of Capecitabine, an Oral, Enzymatically...of Metastatic Breast Cancer, is an original...the viability of capecitabine (Xeloda(R); Hoffmann-...treatment option for breast cancer patients. According...Many metastatic breast cancer patients who had...230 ...
|
|
FDA approves Tykerb for advanced breast cancer patients.
M2 Presswire;
March 14, 2007 ;
544 words
......2007-US FDA: FDA approves Tykerb for advanced breast cancer patients(C)1994-2007 M2 COMMUNICATIONS...for patients with advanced, metastatic breast cancer that is HER2 positive (tumors that exhibit...Cancer Society, about 180,000 new cases of breast cancer are diagnosed each year. ...
|
|
|
FDA Approves Ixempra for Advanced Breast Cancer Patients.
M2 Presswire;
October 23, 2007 ;
548 words
......Approves Ixempra for Advanced Breast Cancer Patients(C)1994-2007 M2...metastatic or locally advanced breast cancer who have not responded...with another cancer drug, capecitabine, in patients who no longer...anthracycline, a taxane and capecitabine. According to the American...about ...
|
|
|
60 Miles Closer to a World Without Breast Cancer.
PR Newswire;
January 24, 2007 ;
700+ words
...Breast Cancer 3-Day Participants Report Intent to Change...Registration is now open for the 2007 Breast Cancer 3-Day Series, a three day, 60-mile walk to raise funds and awareness for breast cancer programs. Registering in January and...
|
|
FDA APPROVES IXEMPRA FOR ADVANCED BREAST CANCER PATIENTS
US Fed News Service, Including US State News;
October 22, 2007 ;
503 words
......metastatic or locally advanced breast cancer who have not responded...with another cancer drug, capecitabine, in patients who no longer...anthracycline, a taxane and capecitabine. According to the American...about 180,000 new cases of breast cancer are diagnosed each year...Ixempra ...
|
|
|
FDA APPROVES TYKERB FOR ADVANCED BREAST CANCER PATIENTS
US Fed News Service, Including US State News;
March 13, 2007 ;
510 words
......for patients with advanced, metastatic breast cancer that is HER2 positive (tumors that exhibit...Cancer Society, about 180,000 new cases of breast cancer are diagnosed each year. Approximately...women die from metastatic HER2 positive breast cancer each year. Tykerb, a new molecular ...
|
|
Experimental agent slows breast cancer growth.(Clinical Rounds)
Skin & Allergy News;
September 1, 2006 ;
664 words
......HER2-positive breast cancer that has become...combined with capecitabine in an international...m.sup.2] of capecitabine on the same schedule...basis to some breast cancer patients. GlaxoSmithKline...and 16 in the capecitabine arm withdrew...lapatinib taken with ...
|
|
New combo may extend breast cancer survival
Drug Topics;
October 15, 2001 ;
700+ words
......with metastatic breast cancer (MBC) who have...combination of Xeloda (capecitabine, Roche) and Taxotere...management of breast cancer as the use of...initially approved capecitabine, an oral chemotherapy...of early-stage breast cancer." The results...full" approval to ...
|
|
Renewed hope for breast cancer survival: new treatments and diagnostic...
Healthy Years;
March 1, 2008 ;
700+ words
......reduce mortality from breast cancer by as much as 35...the diagnosis of breast cancer is technology that...who have metastatic breast cancer (cancer that has...at the San Antonio Breast Cancer Symposium in December...decisions about which breast cancer ...
|
|
Genetics of breast cancer
Mayo Clinic Proceedings;
January 1, 1997 ;
700+ words
...Familial breast cancer is characterized by young age at diagnosis, an increased risk of bilateral breast cancer, an increasing risk in conjunction...cancer. At least eight candidate breast cancer susceptibility genes have been identified...
|
|
|
FDA Approves TYKERB(R) (lapatinib) in Combination With Xeloda(R)...
PR Newswire;
March 13, 2007 ;
700+ words
......with Xeloda(R) (capecitabine), for the treatment...or metastatic breast cancer whose tumors overexpress...ErbB2) positive breast cancer. The data clearly...combination with capecitabine, is effective...18.6 weeks on capecitabine alone in women...ErbB2) positive breast ...
|
See all results.
Or, try our
Advanced Search.
|